It’s great living in the future!

https://nyulangone.org/news/adding-new-vaccine-type-leading-immunotherapy-dramatically-reduced-melanoma-recurrence

NYU Langone Health System announced that a new therapy that combines mRNA technology with immunotherapy reduces the recurrence of melanoma by 44%

This is a stage 2 trial

”Among 107 study subjects who were injected with both the experimental vaccine, called mRNA-4157/V940, and the immunotherapy pembrolizumab, the cancer returned in 24 subjects (22.4 percent) within 3 years of follow-up, compared with 20 out of 50 (40 percent) who received only pembrolizumab.”

Congrats to Dr. Weber and his team!